Aldeyra plans reproxalap phase 3 after wrapping up dry eye disease trial

Aldeyra Therapeutics’ reproxalap has improved ocular dryness and discomfort in patients with dry eye disease in a phase 2b clinical trial. The results tee Aldeyra up to move the aldehyde-binding small molecule into phase 3 next year.